You are subscribed to the Drug Topics Community Pharmacists' Report. Unsubscribe here.

Drug Topics Community Pharmacists' Report

Print Subscribe

Digital Edition Subscribe

January 15, 2013

Web Version  |  Digital Edition  |  Share with a colleague

Facebook Like   Twitter Tweet

Top article

Opioids, MD dispensing drive workers' comp costs

Opioid use and physician dispensing top the list of cost drivers for workers' compensation pharmacy programs across the country. Most workers' compensation programs have instituted programs to manage opioid use and abuse. But physician dispensing of repackaged drugs is beyond control in some states. » More

Continuing Education

New CPE Series: January activity available now

Welcome to the fifth activity in our CPE series: Medication Therapy Management (MTM) in Patients with Diabetes, which has been designed for pharmacists who take care of patients with diabetes. You can earn up to 14 credits from September 2012-March 2013 with 7 monthly knowledge-based activities. The January activity covers macrovascular and microvascular complications of diabetes mellitus.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login.

Announcement: Welcome to the new user registration process. This new process requires all pharmacists and pharmacy technicians to provide or update their NABP e-Profile ID in order to electronically keep track of CPE credits from ACPE-accredited providers. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net. This profile will enable you to have one login for all the NABP programs and services you will need throughout your career.

Today's Headlines

NYC hospitals limit outpatient opioids to 3-day Rx

To help prevent opioid abuse, New York City hospitals will be limiting opioid prescriptions dispensed from its emergency departments to a three-day supply, will not be prescribing long-acting opioids, and will not be refilling lost, stolen, or destroyed prescriptions, according to new voluntary emergency room guidelines that were made available on Jan. 10. » More

New anti-diarrheal drug for HIV/AIDS patients

FDA's recent approval of crofelemer (Fulyzaq, Salix Pharmaceuticals, under license from Napo Pharmaceuticals), 125-mg delayed-release tablets, the first anti-diarrheal drug for HIV/AIDS patients taking antiretroviral therapy (ART), is a significant step forward in addressing the unmet medical need of people with HIV/AIDS on ART who experience noninfectious diarrhea, which often can lead to reduced treatment compliance.
» More

Color of generic drugs may affect adherence

Changes in tablet color significantly increase the odds that patients will stop taking their medications, according to a study published online first Dec. 31, 2012, in JAMA Internal Medicine.
» More

TAKE OUR SURVEY

Are you counseling more oncology patients to help them with their medication regimens?

- Yes
- No

Click Here to let us know.

 
Advertisement

Check these out too

Influenza hits two thirds of states hard

ACA opens door to charge professional fees

Better hypertension control in U.S. adults

"Meaningful Use" incentive program goals

Voices

Anticoagulation Update

JP at Large: Loaded doesn't kill you

View from the Zoo: Goal of improved health may fall short despite increased pharmacy workload

Viewpoints: Guest columnists' commentary

Regulatory and Legal: News and analysis

Meetings and Events

 
Powered by Modern Medicine Advanstar Medical Communications Group